14.19
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Amylyx Pharmaceuticals prices $175M public offering - MSN
Using flow based indicators on Amylyx Pharmaceuticals Inc.July 2025 Reactions & Weekly Hot Stock Watchlists - newser.com
Using economic indicators to assess Amylyx Pharmaceuticals Inc. potentialJuly 2025 Catalysts & Safe Capital Investment Plans - newser.com
Will Amylyx Pharmaceuticals Inc. stock continue upward momentumMarket Volume Report & Daily Entry Point Trade Alerts - newser.com
Amylyx Pharmaceuticals, Inc. Securities Lawsuit Investigation - Claim Depot
Published on: 2025-10-13 09:41:01 - newser.com
Why Amylyx Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Volume & Daily Growth Stock Tips - newser.com
Attention Long-Term Shareholders of Amylyx Pharmaceuticals, - GlobeNewswire
Will Amylyx Pharmaceuticals Inc. stock deliver better than expected guidance2025 Volatility Report & Smart Allocation Stock Tips - newser.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Shares Up 9.6%Should You Buy? - MarketBeat
Key metrics from Amylyx Pharmaceuticals Inc.’s quarterly dataWeekly Profit Analysis & Fast Entry Momentum Alerts - newser.com
Will Amylyx Pharmaceuticals Inc. continue its uptrendJuly 2025 Trends & Safe Capital Growth Plans - newser.com
Best data tools to analyze Amylyx Pharmaceuticals Inc. stockJuly 2025 Outlook & Fast Entry and Exit Trade Plans - newser.com
Leerink Partnrs Has Bullish Forecast for AMLX Q3 Earnings - MarketBeat
How supply chain issues affect Amylyx Pharmaceuticals Inc. stockBond Market & Accurate Buy Signal Alerts - newser.com
Could Legal Scrutiny of AMLX’s Disclosures Reshape Management Credibility at Amylyx Pharmaceuticals? - simplywall.st
Institutional scanner results for Amylyx Pharmaceuticals Inc.Weekly Stock Report & High Yield Stock Recommendations - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Amylyx Pharmaceuticals (NASDAQ:AMLX) - MarketBeat
MarketsMedicine Hat News - FinancialContent
Amylyx Pharmaceuticals (AMLX): A Fresh Look at Valuation Following New Legal Investigation - Sahm
Amylyx Faced With Big Rally Reality Check: Why I Choose To Hold (NASDAQ:AMLX) - Seeking Alpha
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 4%What's Next? - MarketBeat
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm - cnhinews.com
Visual analytics tools that track Amylyx Pharmaceuticals Inc. performanceQuarterly Earnings Summary & Long-Term Safe Investment Ideas - newser.com
Have Amylyx Pharmaceuticals Insiders Been Selling Stock? - simplywall.st
B of A Securities Maintains Amylyx Pharmaceuticals (AMLX) Buy Recommendation - Nasdaq
Amylyx drops clinical program for neuro disorder after trial readout - MSN
Amylyx Will Battle Investor Suit Over Revoked ALS Treatment (1) - Bloomberg Law News
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Expected to Rise, Bank of America Analyst Says - MarketBeat
Amylyx stock price target raised to $16 from $14 at BofA Securities - Investing.com
BofA Securities Maintains Amylyx Pharmaceuticals(AMLX.US) With Buy Rating, Raises Target Price to $16 - 富途牛牛
Strategic Growth and Financial Flexibility Position Amylyx Pharmaceuticals for Success: Buy Rating with $16 Price Target - TipRanks
Amylyx Pharmaceuticals Executives Cash In on Major Stock Sales! - TipRanks
Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Sells $128,712.24 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) Insider Camille Bedrosian Sells 12,039 Shares - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CFO Sells $154,674.70 in Stock - MarketBeat
Amylyx Pharmaceuticals (NASDAQ:AMLX) CEO Justin Klee Sells 29,975 Shares - MarketBeat
Amylyx Pharmaceuticals Inc Stock Analysis and ForecastVolume Spike Alerts & Free Trading Psychology Sessions - earlytimes.in
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price Down 6.5%Here's What Happened - MarketBeat
H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) - MSN
Amylyx Pharmaceuticals Reaches Analyst Target Price - Nasdaq
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):